Prevalence of pathogenic germline variants in women with non-familial unilateral triple-negative breast cancer

Research Article

Open Access Gateway Rhiem K. · Zachariae S. · Waha A. · Grill S. · Hester A. · Golatta M. · van Mackelenbergh M. · Fehm T. · Schlaiß T. · Ripperger T. · Ledig S. · Meisel C. · Speiser D. · Veselinovic K. · Schröder C. · Witzel I. · Gallwas J. · Weber B.H.F. · Solbach C. · Aktas B. · Hahnen E. · Engel C. · Schmutzler R.
Abstract

Introduction: International guidelines recommend genetic testing for women with familial breast cancer at an expected prevalence of pathogenic germline variants (PVs) of at least 10%. In a study sample of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), we have previously shown that women with TNBC diagnosed before the age of 50 years but without a family history of breast or ovarian cancer (sTNBC) meet this criterion. The present study investigates the PV prevalence in BRCA1, BRCA2 and nine additional can-cer predisposition genes in an extended sTNBC study sample including a cohort of women with a later age at sTNBC diagnosis. Patients and methods: In 1600 women with sTNBC (median age at diagnosis 41 years, range 19-78 years) we investigated the association between age at diagnosis and PV occur-rence in cancer predisposition genes using logistic regression. Results: 260 sTNBC patients (16.2%) were found to have a PV in cancer predisposition genes (BRCA1: n=170 [10.6%]; BRCA2: n=46 [2.9%], other: n=44 [2.8%]). The PV prevalence in women diagnosed between 50 and 59 years (n=194) was 11.3% (22/194). Logistic regression showed a significant increase in PV prevalence with decreasing age at diagnosis (OR 1.41 per 10 years younger age at diagnosis; 95%CI 1.21-1.65; p

The Author(s). Published by S. Karger AG, Basel

References Bilani N, Zabor EC, Elson L, Elimimian EB, Nahleh Z. Breast cancer in the United States: a cross-sectional overview. J Cancer Epidemiol. 2020;2020:6387378. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst. 2010;102(24):1874–8. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543–61. Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018 Feb;19(2):169–80. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73(7):2025–30. Zhang J, Sun J, Chen J, Yao L, Ouyang T, Li J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5,931 Chinese women with breast cancer.Breast Cancer Res Treat. 2016;158(3):455–62. Couch FJ, Wang X, McGuffog L, Dicks E, Olswold C, Radice P, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013;9(3):e1003212. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707–14. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. 2013. Clinical guideline (CG164)last updated: 20. November 2019,accessed: 27., Published: Recommendations | Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | Guidance | NICE. Onkologie L, Krebsgesellschaft D, Deutsche Krebshilfe AWMF. S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. Version 4.4, 2021. AWMF Registernummer: 032-045OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/(abgerufen am: 13.11.2022. Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016 Jul;53(7):465–71. Epub 2016 Feb 29. Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018;18(1):265. Hauke J, Horvath J, Groß E, Gehrig A, Honisch E, Hackmann K, et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med. 2018 Apr;7(4):1349–1358. Epub 2018 Mar 9. Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999;105(1–2):72–8. Arnold N, Gross E, Schwarz-Boeger U, Pfisterer J, Jonat W, Kiechle M, et al. A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. Hum Mutat. 1999;14(4):333–9. Hauke J, Wappenschmidt B, Faust U, Niederacher D, Wiesmüller L, Schmidt G, et al. Aktualisierte Kriterien des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zur Klassifizierung von Keimbahn-Sequenzvarianten in Risikogenen für familiären Brust- und Eierstockkrebs. Senologie - Z für Mammadiagnostik -therapie. 2021;18(02):136–62. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282–91. Spurdle AB, Healey S, Devereau A, Hogervorst FBL, Monteiro ANA, Nathanson KL, et al. ENIGMA: evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012;33(1):2–7. Wappenschmidt B, Hauke J, Faust U, Niederacher D, Wiesmüller L, Schmidt G, et al. Criteria of the German consortium for hereditary breast and ovarian cancer for the classification of germline sequence variants in risk genes for hereditary breast and ovarian cancer. Geburtshilfe Frauenheilkd. 2020;80(4):410–29. Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. The Am Statistician. 1998;52(2):119–26. R Core Team. R. A language and environment for statistical computing. Vienna, Austria; 2021. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–11. Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16(6):638–44. Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, et al. Age- and tumor subtype-specific breast cancer risk estimates for chek2*1100delc carriers. J Clin Oncol. 2016;34(23):2750–60. Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst. 2018;110(8):855–62. Article / Publication Details

Received: August 19, 2022
Accepted: January 02, 2023
Published online: January 06, 2023

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 3

ISSN: 1661-3791 (Print)
eISSN: 1661-3805 (Online)

For additional information: https://www.karger.com/BRC

Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif